Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences, Financial Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences, Inc. (DTIL) has granted Caribou Biosciences a non-exclusive, worldwide license to use one of Precision's cell therapy patent families with CRISPR for human therapeutics. Financial terms were not disclosed.
February 20, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precision BioSciences has entered into a licensing agreement with Caribou Biosciences for CRISPR cell therapy patents.
The licensing agreement with Caribou Biosciences could potentially increase Precision BioSciences' licensing revenue and enhance its position in the CRISPR and gene editing market. However, without financial terms disclosed, the immediate financial impact is uncertain, but the strategic value and potential for future revenue through sublicensing could be significant.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90